Patient characteristics
| . | AERD . | ATA . | Nonasthmatic . |
|---|---|---|---|
| No. | n = 15 | n = 13 | n = 9 |
| Sex (male:female) | 7:8 | 4:9 | 5:4 |
| Median age, y (range) | 45 (20-65) | 37 (22-76) | 34 (22-52) |
| Atopic (n) | 9/15 | 10/13 | 3/9 |
| Baseline FEV1 (mean % predicted ± SD) | 82 ± 9 | 88 ± 15 | NA |
| Receiving daily inhaled corticosteroids (n) | 15/15 | 12/13 | 0/9 |
| Receiving daily oral corticosteroids (n) | 2/15 | 1/13 | 0/9 |
| Receiving daily long-acting β-agonists (n) | 10/15 | 7/13 | 0/9 |
| Eosinophils (mean % of blood granulocytes ± SD) | 15.1 ± 9.0 | 10.4 ± 6.0 | 6.4 ± 2.7 |
| . | AERD . | ATA . | Nonasthmatic . |
|---|---|---|---|
| No. | n = 15 | n = 13 | n = 9 |
| Sex (male:female) | 7:8 | 4:9 | 5:4 |
| Median age, y (range) | 45 (20-65) | 37 (22-76) | 34 (22-52) |
| Atopic (n) | 9/15 | 10/13 | 3/9 |
| Baseline FEV1 (mean % predicted ± SD) | 82 ± 9 | 88 ± 15 | NA |
| Receiving daily inhaled corticosteroids (n) | 15/15 | 12/13 | 0/9 |
| Receiving daily oral corticosteroids (n) | 2/15 | 1/13 | 0/9 |
| Receiving daily long-acting β-agonists (n) | 10/15 | 7/13 | 0/9 |
| Eosinophils (mean % of blood granulocytes ± SD) | 15.1 ± 9.0 | 10.4 ± 6.0 | 6.4 ± 2.7 |
NA indicates not applicable.